Clinical Trials

462 enrolled 30 charts

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03976323 2026-02-25

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

1,003 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

NCT03976362 2026-02-25

KEYLYNK-008

851 enrolled 25 charts

Carcinoma

NCT04221945 2026-02-20

KEYNOTE-A18

1,060 enrolled 30 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04738487 2026-02-20

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

1,264 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03829332 2026-02-19

LEAP-007

623 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05005442 2026-02-19

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

Other hematologic neoplasm

192 enrolled 22 charts

Hematologic Neoplasms

NCT02684292 2026-02-18

MK-3475-204

304 enrolled 2 FDA

Lymphoid

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT03820986 2026-02-09

LEAP-003

674 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03598608 2026-02-05

MK-4280-003

137 enrolled

Lymphoid

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03713593 2026-02-05

LEAP-002

794 enrolled 30 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT03829319 2026-02-05

LEAP-006

761 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03898180 2026-02-05

LEAP-011

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04700124 2026-02-05

KEYNOTE-B15

808 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT04776148 2026-02-05

MK-7902-017

563 enrolled 32 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05226598 2026-02-05

MK-7684A-007

739 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03040999 2026-02-04

KEYNOTE-412

804 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03867084 2026-02-04

KEYNOTE-937

959 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT04619797 2026-02-03

SKYSCRAPER-06

Phase 2/3 Completed

542 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02853331 2026-02-02

KEYNOTE-426

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT03884101 2026-02-02

LEAP-001

842 enrolled 25 charts

Gynecologic

Endometrial Neoplasms

NCT04260529 2026-01-29

CICILIA

60 enrolled 18 charts

Neoplasms

NCT05174585 2026-01-06

JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

21 enrolled

Other solid neoplasm

Solid Tumor

NCT05307874 2025-12-24

EVICTION-2

56 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT04889118 2025-12-23

LEAP-003

131 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05165433 2025-12-16

FORTIFY

Phase 1 Completed

14 enrolled

Carcinoma, Neoplasm Metastasis

NCT03310957 2025-12-12

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

185 enrolled 23 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02362035 2025-12-11

KEYNOTE145

LymphoidOther hematologic neoplasmPlasma cell

161 enrolled 29 charts

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04811027 2025-12-11

TACTI-003

171 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04381650 2025-12-10

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

161 enrolled 44 charts

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT04428151 2025-12-04

LEAP-009

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

89 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04704219 2025-12-03

KEYNOTE-B61

160 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05383170 2025-11-28

Catalyst

6 enrolled 11 charts

Neoplasms

NCT04165083 2025-11-26

MK-3475-01B

102 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04570332 2025-11-26

SPOTLIGHT203

42 enrolled 12 charts

Melanoma

NCT02625961 2025-11-21

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

296 enrolled

Urinary Bladder Neoplasms

NCT04796194 2025-11-20

ATLAS-IT-05

23 enrolled

Melanoma

NCT03797326 2025-11-17

LEAP-005

BreastCNSGastrointestinalGynecologic

611 enrolled 27 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03486301 2025-11-12

EIK1001

Phase 1 Completed

87 enrolled